The objective of this study was: (1) to assess frequency of renal involvement in CAPS; (2) to identify a potential association of renal outcome with genetic mutations on the NLRP3 gene; and (3) to evaluate the impact of anti-IL-1 therapy on clinical symptoms and inflammatory marker as well as renal outcome. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.